

**EFFECT OF EXOGENOUSLY ADMINISTERED
HYDROGEN SULPHIDE (H₂S) ON PLASMA
CONCENTRATION OF NUCLEAR FACTOR-
KAPPA B (NF-κB) AND INTERCELLULAR
ADHESION MOLECULE-1 (ICAM-1) IN A RAT
MODEL OF RENAL ISCHEMIA REPERFUSION
INJURY**

by

SYED FAYAZ UL HAQ HASHMI

**Thesis submitted in fulfilment of the requirements
for the degree of
Master of Science**

March 2017

**EFFECT OF EXOGENOUSLY ADMINISTERED
HYDROGEN SULPHIDE (H₂S) ON PLASMA
CONCENTRATION OF NUCLEAR FACTOR-
KAPPA B (NF-κB) AND INTERCELLULAR
ADHESION MOLECULE-1 (ICAM-1) IN A RAT
MODEL OF RENAL ISCHEMIA REPERFUSION
INJURY**

SYED FAYAZ UL HAQ HASHMI

UNIVERSITI SAINS MALAYSIA

2017

ACKNOWLEDGEMENT

First of all I would like to thank Almighty ALLAH, who gave me the strength to undertake this research.

It gives me immense pleasure to acknowledge my deepest gratitude and appreciation to my supervisor Prof. Dr. Munavvar Zubaid Abdul Sattar for giving me an opportunity to work in cardiovascular and renal physiology research laboratory (CRPRLab). I would like to pay my heartiest thanks for his advice, guidance and availability of his experience and knowledge in this field. I feel very lucky to be a student of such a knowledgeable scientist who encouraged me and gave me all the support without hesitation.

I would like to extend my deepest gratitude to my co-supervisor Dr. Hassaan Anwer Rathore because without his sincere guidance it would have been difficult for me to complete this research work in such a short span of time. I remember my initial days in CRPRLab when i had neither research experience nor detailed knowledge of renal physiology and he showed tremendous patience and guided me with great attention. I really appreciate your generosity and your kind supervision from the first day till date in supervising and financially supporting this research work from your grant.

I would also like to thank Professor Emeritus Dr. Edward Jones, University College Cork, Ireland. I am very lucky to have received guidance from a great scientist like him who helped me with his valuable suggestions regarding my research work whenever he visited CRPRLab.

I wish to thank the Institute of Postgraduate Studies (IPS) for providing USM

Graduate Assistantship (GA) to me which helped me a lot to reach my goal and smooth sailing of my research journey. I also acknowledge the support given by non-academic staff of the School of Pharmaceutical Sciences as without their assistance the progress of my work would have been slower.

I would also like to thank my lab colleagues, Sheryar Afzal, Safia Akhtar Khan, Ibrahim Lazhari and Yamuna Sucedaram for being there to offer me help and support throughout my study. I am grateful to them for the hours we shared in discussion on scientific, life and personal development. We really spent a good time together. My special thanks go to Ashfaq Ahmad because he was always like a big brother to me. He always treated me not like a junior member of the lab but like a younger brother and guided me throughout my research work starting from proposal defense to thesis writing. His useful suggestions made my research work very easy.

My sincere gratitude goes to my family, especially my parents who dedicated their lives to loving and caring for me and my sisters who always prayed for my success. Indeed just words are not sufficient to thank their sacrifice and patience.

Last but not the least my sincere thanks to my elder brother Syed Waqar Ul Haq Hashmi for financial and moral support of my studies. Without his support it would have been difficult to finish the task.

TABLE OF CONTENTS

ACKNOWLEDGEMENT	ii
TABLE OF CONTENTS	iv
LIST OF FIGURES	xi
LIST OF TABLES	xvii
LIST OF ABBREVIATIONS	xviii
ABSTRAK	xxii
ABSTRACT	xxiv
CHAPTER 1	1
INTRODUCTION	1
1.1 Kidney	1
1.1.1 Anatomy of the kidney	1
1.1.2 Renal physiology	3
1.2 Ischemia reperfusion injury	4
1.2.1 Ischemia	4
1.2.1 (a) Myocardial ischemia	4
1.2.1 (b) Cerebral ischemia	5
1.2.1 (c) Critical limb ischemia	5
1.2.1 (d) Hepatic ischemia	5
1.2.1 (e) Renal ischemia	5
1.2.2 Reperfusion injury	6
1.3 Renal failure	9
1.3.1 Chronic renal failure	9
1.3.2 Acute renal failure	9
1.3.2 (a) Pre-renal cause	10
1.3.2 (b) Intra-renal cause	10
1.3.2 (c) Post-renal cause	11
1.3.3 Drugs-induced acute renal failure	11
1.3.3 (a) Cisplatin induced acute renal failure	12
1.4 Hypertension	13
1.4.1 Primary hypertension	14
1.4.2 Secondary hypertension	15

1.4.2 (a) L-NAME induced hypertension	15
1.5 Inflammation	17
1.5.1 Acute inflammation	19
1.5.1 (a) Vascular changes	20
1.5.1 (b) Cellular events	20
1.5.2 Chronic inflammation	21
1.5.2 (a) Non-specific chronic inflammation	21
1.5.2 (b) Specific chronic inflammation	22
1.6 Ischemia reperfusion injury and inflammation	23
1.7 The role of ROS in ischemia reperfusion injury	24
1.8. Inter cellular adhesion molecules	25
1.8.1 Inter cellular adhesion molecule-1	26
1.8.1 (a) Concentration of ICAM-1	27
1.8.1 (b) Function of ICAM-1	27
1.8.1 (c) Stimulators of ICAM-1	28
1.8.1 (d) ICAM-1 and ROS	29
1.8.1 (e) ICAM-1 and ischemia reperfusion injury	30
1.8.2 Inter cellular adhesion molecule-2	31
1.8.3 Inter cellular adhesion molecule-3	31
1.8.4 Inter cellular adhesion molecule-4	32
1.8.5 Inter cellular adhesion molecule-5	32
1.9 Nuclear factor-kappa B (NF-kB)	33
1.9.1 Regulation of Nuclear factor-kappa B (NF-kB)	34
1.9.1 (a) NF-kB and Rel proteins	34
1.9.1 (b) I κ B proteins	34
1.9.2 Functions of NF-kB	35
1.9.3 Stimulation of NF-kB	35
1.9.4 Effect of NF-kB on ICAM-1 concentration	36
1.9.5 NF-kB and ischemia reperfusion injury	36
1.10 Hydrogen sulphide	37
1.10.1 Production of hydrogen sulphide	38

1.10.1 (a) Enzymatic production	38
1.10.1 (b) Non enzymatic production	40
1.10.2 Metabolism of hydrogen sulphide	40
1.10.3 Physiological concentration of hydrogen sulphide	41
1.10.4 Functions of hydrogen sulphide	42
1.10.4 (a) H ₂ S induced vasorelaxation	42
1.10.4 (b) Role of H ₂ S in hypertension	43
1.10.4 (c) Role of H ₂ S in oxidative stress	43
1.10.4 (d) Effect of H ₂ S on inflammation	44
1.10.4 (e) Effect of H ₂ S on ICAM-1 expression	45
1.10.4 (f) Effect of H ₂ S on NF-kB concentration	46
1.10.4 (g) Effect of H ₂ S on renal ischemia reperfusion injury	47
1.11 Inhibitors of H ₂ S	48
1.11.1 dL-propargylglycine (PAG)	49
1.12 Rationale of the study	49
1.13 Problem statement	50
1.14 Hypothesis	50
1.15 Aims and objectives of the study	51
CHAPTER 2	52
MATERIALS AND METHODS	52
2.1 Subjects of the study	52
2.2 Groups of the experimental rats	53
2.3 Overview of the groups <i>in vivo</i> study	56
2.4 Measurement of non-invasive blood pressure (NIBP)	56
2.5 Treatment with exogenous NaHS (H ₂ S donor)	57
2.6 Induction of hypertension by L-NAME (N-Nitro-L-Arginine-Methyl Ester)	58
2.7 Cisplatin induced acute renal failure (ARF)	58
2.8 Administration of dL-Propargylglycine (PAG)	58
2.9 Metabolic data collection	59
2.10 Acute surgical experiment	59
2.10.1 Pulse wave velocity (PWV) measurement	63
2.10.1 (a) Propagation distance	64
2.10.1 (b) Propagation time	64

2.11 Renal function parameters	65
2.11.1 Measurement of creatinine level (plasma and urine)	65
2.11.2 Measurement of sodium level (urine and plasma)	67
2.11.3 Measurement of potassium level (urine and plasma)	67
2.11.4 Urine flow rate	68
2.11.5 Creatinine clearance	68
2.11.6 Absolute urinary potassium and sodium excretion	69
2.11.7 Fractional potassium (FE_K) and fractional sodium (FE_{Na}) excretion (%)	70
2.11.8 Urinary sodium to urinary potassium (U_{Na^+}/U_{K^+}) ratio	70
2.12 Measurement of H_2S concentration in the plasma	71
2.12.1 Standard curve for H_2S	72
2.13 Measurement of oxidative stress parameters	73
2.13.1 Malondialdehyde (MDA)	74
2.13.2 Total superoxide dismutase (T-SOD)	76
2.13.3 Glutathione (GSH)	78
2.14 Rat sICAM-1/CD 54 immunoassay	80
2.14.1 Reagent preparation	81
2.14.1 (a) Calibrator diluent RD5-26	81
2.14.1 (b) Wash buffer	81
2.14.1 (c) Rat sICAM-1 control	81
2.14.1 (d) Substrate solution	82
2.14.1 (e) Rat sICAM-1 standard	82
2.14.2 Sample preparation for the ICAM-1 assay	83
2.14.3 Assay procedure for ICAM-1 ELISA	84
2.14.4 Standard curve for ICAM-1 standard	85
2.15 Rat nuclear factor-kappa B (NF- κ B) immunoassay	86
2.15.1 Reagent preparation	87
2.15.1 (a) Biotin-antibody	87
2.15.1 (b) HRP-avidin	88
2.15.1 (c) Wash buffer	88
2.15.1 (d) Preparation of standard solution	88

2.15.2 Sample preparation for NF-kB assay	89
2.15.3 Assay procedure for NF-kB ELISA	90
2.15.4 Construction of standard curve for NF-kB standard	91
2.16 Statistical analysis	93
2.17 List of chemicals	93
2.18 List of equipments	95
CHAPTER 3	97
RESULTS	97
3.1 Physiological data	97
3.1.1 Body weight	97
3.1.2 Water intake	98
3.1.3 Urine out put	99
3.1.4 Urine flow rate	100
3.2 Systemic haemodynamics	102
3.2.1 Systolic blood pressure	102
3.2.2 Diastolic blood pressure	103
3.2.3 Mean arterial pressure	104
3.2.4 Heart rate	105
3.2.5 Pulse pressure	105
3.3 Renal function parameters	106
3.3.1 Plasma sodium	106
3.3.2 Urinary sodium	107
3.3.3 Plasma potassium	108
3.3.4 Urinary potassium	109
3.3.5 Absolute urinary sodium excretion	110
3.3.6 Absolute urinary potassium excretion	111
3.3.7 Fractional excretion of sodium	112
3.3.8 Fractional excretion of potassium	113
3.3.9 Urinary sodium to urinary potassium ratio	114
3.3.10 Plasma creatinine	115

3.3.11 Urinary creatinine	116
3.3.12 Creatinine clearance	117
3.4 Hydrogen sulphide concentration in plasma	119
3.5 Renal function parameters in pre-ischemia and reperfusion phases	120
3.5.1 Plasma sodium in pre-ischemia and reperfusion phases	120
3.5.2 Urinary sodium in pre-ischemia and reperfusion phases	121
3.5.3 Plasma potassium in pre-ischemia and reperfusion phases	123
3.5.4 Urinary potassium in pre-ischemia and reperfusion phases	124
3.5.5 Fractional excretion of sodium in pre-ischemia and reperfusion phases	125
3.5.6 Fractional excretion of potassium in pre-ischemia and reperfusion phases	126
3.5.7 Urinary sodium to urinary potassium (U_{Na+}/U_{K+}) ratio in pre-ischemia and reperfusion phases	128
3.5.8 Plasma creatinine in pre-ischemia and reperfusion phases	129
3.5.9 Urinary creatinine in pre-ischemia and reperfusion phases	131
3.6 Changes in systemic haemodynamics in pre-ischemia and reperfusion phases	132
3.6.1 Changes in SBP in pre-ischemia and reperfusion phases	132
3.6.2 Changes in DBP in pre-ischemia and reperfusion phases	133
3.6.3 Changes in MAP in pre-ischemia and reperfusion phases	134
3.6.4 Changes in heart rate in pre-ischemia and reperfusion phases	134
3.6.5 Changes in pulse pressure in pre-ischemia and reperfusion phases	135
3.7 Changes in RCBP in pre-ischemia and reperfusion phases	135
3.8 Changes in PWV in pre-ischemia and reperfusion phases	137
3.9 Changes in oxidative stress parameters in pre-ischemia and reperfusion phases	138
3.9.1 Changes in MDA concentration in pre-ischemia and reperfusion phases	138
3.9.2 Changes in T-SOD level in pre-ischemia and reperfusion phases	139
3.9.3 Changes in GSH concentration in pre-ischemia and reperfusion phases	141
3.10 Changes in ICAM-1 concentration in pre-ischemia and reperfusion phases	143
3.11 Changes in NF-kB concentration in pre-ischemia and reperfusion phases	144
3.12 Changes in kidney index	146

CHAPTER 4	236
DISCUSSION	236
4.1 Physiological data	238
4.2 Systemic haemodynamics	240
4.3 Renal function parameters	242
4.4 Concentration of H ₂ S in plasma	246
4.5 Renal function parameters in pre-ischemia and reperfusion phases	248
4.6 Changes in RCBP in pre-ischemia and reperfusion phases	251
4.7 Changes in PWV in pre-ischemia and reperfusion phases	253
4.8 Changes in oxidative stress parameters in pre-ischemia and reperfusion phases	254
4.9 Changes in ICAM-1 concentration in pre-ischemia and reperfusion phases	261
4.10 Changes in NF-kB concentration in pre-ischemia and reperfusion phases	263
4.11 Changes in kidney index	266
CHAPTER 5	268
CONCLUSION	268
REFERENCES	271
APPENDICES	
LIST OF PUBLICATIONS	

LIST OF FIGURES

	Page
Figure 1.1 Anatomy of the human kidneys	3
Figure 1.2 Schematic enzymatic production of H ₂ S	39
Figure 2.1 Experimental groups of study protocol	54
Figure 2.2 Schematic diagram of acute surgical experiment	63
Figure 2.3 Diagrammatic presentation of propagation distance and propagation time for the calculation of PWV	65
Figure 2.4 Calibration curve for H ₂ S standard	73
Figure 2.5 Schematic diagram for standard stock solution of two-fold dilution series for ICAM-1 standard.	83
Figure 2.6 Standard curve for ICAM-1	86
Figure 2.7 Schematic diagram for standard stock solution of two-fold dilution series for NF-kB standard	89
Figure 2.8 Standard curve for NF-kB	92
Figure 3.1 Body weight of NRF and RF groups of WKY rats	148
Figure 3.2 Water intake of NRF and RF groups of WKY rats	149
Figure 3.3 Urine output of NRF and RF groups of WKY rats	150
Figure 3.4 SBP of NRF and RF groups of WKY rats	151
Figure 3.5 DBP of NRF and RF groups of WKY rats	152
Figure 3.6 MAP of NRF and RF groups of WKY rats	153
Figure 3.7 HR of NRF and RF groups of WKY rats	154
Figure 3.8 PP of NRF and RF groups of WKY rats	155
Figure 3.9 Plasma sodium of NRF and RF groups of WKY rats	156
Figure 3.10 Urinary sodium of NRF and RF groups of WKY rats	157

Figure 3.11	Plasma potassium of NRF and RF groups of WKY rats	158
Figure 3.12	Urinary potassium of NRF and RF groups of WKY rats	159
Figure 3.13	Absolute urinary sodium excretion of NRF and RF groups of WKY rats	160
Figure 3.14	Absolute urinary potassium excretion of NRF and RF groups of WKY rats	161
Figure 3.15	Fractional excretion of sodium excretion of NRF and RF groups of WKY rats	162
Figure 3.16	Fractional excretion of potassium excretion of NRF and RF groups of WKY rats	163
Figure 3.17	Urinary sodium to urinary potassium ratio of NRF and RF groups of WKY rats	164
Figure 3.18	Urine flow rate of NRF and RF groups of WKY rats	165
Figure 3.19	Plasma creatinine of NRF and RF groups of WKY rats	166
Figure 3.20	Urinary creatinine of NRF and RF groups of WKY rats	167
Figure 3.21	Creatinine clearance of NRF and RF groups of WKY rats	168
Figure 3.22	Plasma H ₂ S of NRF and RF groups of WKY rats	169
Figure 3.23	Percentage change of SBP in pre-ischemia and reperfusion phases of NRF and RF groups of WKY rats	170
Figure 3.24	Percentage change of DBP in pre-ischemia and reperfusion phases of NRF and RF groups of WKY rats	171
Figure 3.25	Percentage change of MAP in pre-ischemia and reperfusion phases of NRF and RF groups of WKY rats	172
Figure 3.26	Percentage change of HR in pre-ischemia and reperfusion phases of NRF and RF groups of WKY rats	173
Figure 3.27	Percentage change of PP in pre-ischemia and reperfusion phases of NRF and RF groups of WKY rats	174
Figure 3.28	Percentage change of RCBP in pre-ischemia and reperfusion phases of NRF and RF groups of WKY rats	175
Figure 3.29	Percentage change of PWV in pre-ischemia and reperfusion phases of NRF and RF groups of WKY rats	176

Figure 3.30	Percentage change of MDA in pre-ischemia and reperfusion phases of NRF and RF groups of WKY rats	177
Figure 3.31	Percentage change of T-SOD in pre-ischemia and reperfusion phases of NRF and RF groups of WKY rats	178
Figure 3.32	Percentage change of GSH in pre-ischemia and reperfusion phases of NRF and RF groups of WKY rats	179
Figure 3.33	Percentage change of ICAM-1 in pre-ischemia and reperfusion phases of NRF and RF groups of WKY rats	180
Figure 3.34	Percentage change of NF-kB in pre-ischemia and reperfusion phases of NRF and RF groups of WKY rats	181
Figure 3.35	Kidney index of NRF and RF groups of WKY rats	182
Figure 3.36	Plasma Na ⁺ in pre-ischemia and reperfusion phases of NRF and RF groups of WKY rats	183
Figure 3.37	Urinary Na ⁺ in pre-ischemia and reperfusion phases of NRF and RF groups of WKY rats	184
Figure 3.38	Plasma K ⁺ in pre-ischemia and reperfusion phases of NRF and RF groups of WKY rats	185
Figure 3.39	Urinary K ⁺ in pre-ischemia and reperfusion phases of NRF and RF groups of WKY rats	186
Figure 3.40	FE _{Na} in pre-ischemia and reperfusion phases of NRF and RF groups of WKY rats	187
Figure 3.41	FE _K in pre-ischemia and reperfusion phases of NRF and RF groups of WKY rats	188
Figure 3.42	Na ⁺ :K ⁺ ratio in pre-ischemia and reperfusion phases of NRF and RF groups of WKY rats	189
Figure 3.43	Plasma creatinine in pre-ischemia and reperfusion phases of NRF and RF groups of WKY rats	190
Figure 3.44	Urinary creatinine in pre-ischemia and reperfusion phases of NRF and RF groups of WKY rats	191
Figure 3.45	Body weight of WKY-CONTROL, WKY-RF and both NRF and RF groups of L-NAME treated rats	192
Figure 3.46	Water intake of WKY-CONTROL, WKY-RF and both NRF and RF groups of L-NAME treated rats	193

Figure 3.47	Urine output of WKY-CONTROL, WKY-RF and both NRF and RF groups of L-NAME treated rats	194
Figure 3.48	SBP of WKY-CONTROL, WKY-RF and both NRF and RF groups of L-NAME treated rats	195
Figure 3.49	DBP of WKY-CONTROL, WKY-RF and both NRF and RF groups of L-NAME treated rats	196
Figure 3.50	MAP of WKY-CONTROL, WKY-RF and both NRF and RF groups of L-NAME treated rats	197
Figure 3.51	HR of WKY-CONTROL, WKY-RF and both NRF and RF groups of L-NAME treated rats	198
Figure 3.52	PP of WKY-CONTROL, WKY-RF and both NRF and RF groups of L-NAME treated rats	199
Figure 3.53	Plasma Na ⁺ of WKY-CONTROL, WKY-RF and both NRF and RF groups of L-NAME treated rats	200
Figure 3.54	Urinary Na ⁺ of WKY-CONTROL, WKY-RF and both NRF and RF groups of L-NAME treated rats	201
Figure 3.55	Plasma K ⁺ of WKY-CONTROL, WKY-RF and both NRF and RF groups of L-NAME treated rats	202
Figure 3.56	Urinary K ⁺ of WKY-CONTROL, WKY-RF and both NRF and RF groups of L-NAME treated rats	203
Figure 3.57	Absolute urinary sodium excretion of WKY-CONTROL, WKY-RF and both NRF and RF groups of L-NAME treated rats	204
Figure 3.58	Absolute urinary potassium excretion of WKY-CONTROL, WKY-RF and both NRF and RF groups of L-NAME treated rats	205
Figure 3.59	FE _{Na} of WKY-CONTROL, WKY-RF and both NRF and RF groups of L-NAME treated rats	206
Figure 3.60	FE _K of WKY-CONTROL, WKY-RF and both NRF and RF groups of L-NAME treated rats	207
Figure 3.61	Na ⁺ :K ⁺ ratio of WKY-CONTROL, WKY-RF and both NRF and RF groups of L-NAME treated rats	208
Figure 3.62	Urine flow rate of WKY-CONTROL, WKY-RF and both NRF and RF groups of L-NAME treated rats	209

Figure 3.63	Plasma creatinine of WKY-CONTROL, WKY-RF and both NRF and RF groups of L-NAME treated rats	210
Figure 3.64	Urinary creatinine of WKY-CONTROL, WKY-RF and both NRF and RF groups of L-NAME treated rats	211
Figure 3.65	Creatinine clearance of WKY-CONTROL, WKY-RF and both NRF and RF groups of L-NAME treated rats	212
Figure 3.66	Plasma H ₂ S of WKY-CONTROL, WKY-RF and both NRF and RF groups of L-NAME treated rats	213
Figure 3.67	Percentage change of SBP in pre-ischemia and reperfusion phases of WKY-CONTROL, WKY-RF and both NRF and RF groups of L-NAME treated rats	214
Figure 3.68	Percentage change of DBP in pre-ischemia and reperfusion phases of WKY-CONTROL, WKY-RF and both NRF and RF groups of L-NAME treated rats	215
Figure 3.69	Percentage change of MAP in pre-ischemia and reperfusion phases of WKY-CONTROL, WKY-RF and both NRF and RF groups of L-NAME treated rats	216
Figure 3.70	Percentage change of HR in pre-ischemia and reperfusion phases of WKY-CONTROL, WKY-RF and both NRF and RF groups of L-NAME treated rats	217
Figure 3.71	Percentage change of PP in pre-ischemia and reperfusion phases of WKY-CONTROL, WKY-RF and both NRF and RF groups of L-NAME treated rats	218
Figure 3.72	Percentage change of RCBP in pre-ischemia and reperfusion phases of WKY-CONTROL, WKY-RF and both NRF and RF groups of L-NAME treated rats	219
Figure 3.73	Percentage change of PWV in pre-ischemia and reperfusion phases of WKY-CONTROL, WKY-RF and both NRF and RF groups of L-NAME treated rats	220
Figure 3.74	Percentage change of MDA in pre-ischemia and reperfusion phases of WKY-CONTROL, WKY-RF and both NRF and RF groups of L-NAME treated rats	221
Figure 3.75	Percentage change of T-SOD in pre-ischemia and reperfusion phases of WKY-CONTROL, WKY-RF and both NRF and RF groups of L-NAME treated rats	222
Figure 3.76	Percentage change of GSH in pre-ischemia and reperfusion phases of WKY-CONTROL, WKY-RF and both NRF and RF groups of L-NAME treated rats	223

Figure 3.77	Percentage change of ICAM-1 in pre-ischemia and reperfusion phases of WKY-CONTROL, WKY-RF and both NRF and RF groups of L-NAME treated rats	224
Figure 3.78	Percentage change of NF-kB in pre-ischemia and reperfusion phases of WKY-CONTROL, WKY-RF and both NRF and RF groups of L-NAME treated rats	225
Figure 3.79	KI of WKY-CONTROL, WKY-RF and both NRF and RF groups of L-NAME treated rats	226
Figure 3.80	Plasma Na ⁺ in pre-ischemia and reperfusion phases of WKY-CONTROL, WKY-RF and both NRF and RF groups of L-NAME treated rats	227
Figure 3.81	Urinary Na ⁺ in pre-ischemia and reperfusion phases of WKY-CONTROL, WKY-RF and both NRF and RF groups of L-NAME treated rats	228
Figure 3.82	Plasma K ⁺ in pre-ischemia and reperfusion phases of WKY-CONTROL, WKY-RF and both NRF and RF groups of L-NAME treated rats	229
Figure 3.83	Urinary K ⁺ in pre-ischemia and reperfusion phases of WKY-CONTROL, WKY-RF and both NRF and RF groups of L-NAME treated rats	230
Figure 3.84	FE _{Na} in pre-ischemia and reperfusion phases of WKY-CONTROL, WKY-RF and both NRF and RF groups of L-NAME treated rats	231
Figure 3.85	FE _K in pre-ischemia and reperfusion phases of WKY-CONTROL, WKY-RF and both NRF and RF groups of L-NAME treated rats	232
Figure 3.86	Na ⁺ :K ⁺ ratio in pre-ischemia and reperfusion phases of WKY-CONTROL, WKY-RF and both NRF and RF groups of L-NAME treated rats	233
Figure 3.87	Plasma Creatinine in pre-ischemia and reperfusion phases of WKY-CONTROL, WKY-RF and both NRF and RF groups of L-NAME treated rats	234
Figure 3.88	Urinary creatinine in pre-ischemia and reperfusion phases of WKY-CONTROL, WKY-RF and both NRF and RF groups of L-NAME treated rats	235

LIST OF TABLES

		Page
Table 1.1	Classification of hypertension	14
Table 1.2	Features of acute and chronic inflammation	22
Table 1.3	Role of various inflammatory mediators	22
Table 2.1	Preparation of sample, standard and blank for measurement of creatinine in urine and plasma	67
Table 2.2	Absorbances of known concentrations (3.125-100 μ M) of NaHS	72
Table 2.3	Assay protocol for MDA calculation	75
Table 2.4	Assay protocol for T-SOD calculation	77
Table 2.5	Assay protocol for GSH calculation	79
Table 2.6	Materials provided in the rat sICAM-1 assay kit	84
Table 2.7	Materials provided in the rat NF-kB ELISA kit	90

LIST OF ABBREVIATIONS

IRI	Ischemia reperfusion injury
I/R	Ischemia reperfusion
ROS	Reactive oxygen species
ARF	Acute renal failure
Cisp	Cisplatin
HTN	Hypertension
NIBP	Non-invasive blood pressure
SBP	Systolic blood pressure
DBP	Diastolic blood pressure
MAP	Mean arterial pressure
HR	Heart rate
PP	Pulse pressure
RCBP	Renal cortical blood perfusion
PWV	Pulse wave velocity
L-NAME	L-nitro arginine methyl ester
NO	Nitric oxide
NOS	Nitric oxide synthase
eNOS	Endothelial nitric oxide synthase
nNOS	Neuronal nitric oxide synthase
$O_2^{\bullet-}$	Superoxide anion
H_2O_2	hydrogen peroxide
$ONOO^-$	Peroxynitrite
OH^{\bullet}	Hydroxyl radical

ICAM-1	Inter cellular adhesion molecule-1
CD 54	Cluster of differentiation
Ig	Immunoglobulin
IL-1	Inter leukin-1
TNF- α	Tumor necrosis factor- α
LFA-1	Lymphocyte function associated antigen-1
NF-kB	Nuclear factor kappa-B
DNA	Deoxyribonucleic acid
mRNA	Messenger ribonucleic acid
IkB	Inhibitory kappa B
H ₂ S	Hydrogen sulphide
CBS	Cystathionine beta synthase
CSE	Cystathionine gamma lyase
3-MST	3-Mercaptopyruvate sulfurtransferase
PAG	dL-propargylglycine
NaHS	Sodium hydrosulphide
WKY	Wistar Kyoto
ATN	Acute tubular necrosis
MDA	Malondialdehyde
T-SOD	Total superoxide dismutase
GSH	Glutathione
G	Grams
mmHg	Millimetre mercury
mg/mL	Milligram per milliliter
μ mol/kg	Micromole per kilogram

mM	Millimole
nmol/mL	Nanomole per milliliter
pg/mL	Picogram per milliliter
Ng	Nanogram
mL/min/kg	Millilitre per minute per kilogram
mg/kg	Milligram per kilogram
O.D	Optical density
HRP	Horse radish peroxidase
i.p.	Intraperitoneal
mL	Millilitre
%	Percentage
m/s	Meter per second
μ M	Micro mole
μ L	Microliter
Ucr.	Urinary creatinine
Pcr.	Plasma creatinine
BW	Body weight
$U_{Na}V$	Absolute urinary sodium excretion
U_KV	Absolute urinary potassium excretion
FE_{Na+}	Fractional excretion of sodium
FE_{K+}	Fractional excretion of potassium
Na:K ratio	Sodium : potassium ratio
D.W	Distal water
W/V	Weight/ per volume
KI	Kidney index

UFR	Urine flow rate
BPU	Blood perfusion unit
PP tubing	Polypropylene tubing
Abs.	Absorbance
Conc.	Concentration
Std	Standard

**KESAN PEMBERIAN HIDROGEN SULFIDA (H₂S) KE ATAS KEPEKATAN
NUKLEAR FAKTOR KAPPA-B (NF-KB) DALAM PLASMA DAN
MOLECUL-1 LEKATAN INTERSEL (ICAM-1) DI DALAM MODEL TIKUS
YANG MENGALAMI KECEDERAAN REPERFUSI ISKEMIA GINJAL**

ABSTRAK

Kajian ini menyelidik kesan pemberian penderma hidrogen sulfida (H₂S), sodium hidrosulphida (NaHS) secara eksogenous ke atas kepekatan nuklear faktor kappa-B (NF-kB) dan molekul-1 interisel (ICAM-1) dalam kecederaan iskemia reperfusi ginjal di dalam tikus normotensif *Wistar Kyoto* (WKY) tanpa kegagalan ginjal (NRF) dan dengan kegagalan ginjal (RF) serta hipertensi aruhan L-nitro-arginin-methyl-ester (L-NAME) di dalam tikus tanpa kegagalan ginjal (NRF) dan dengan kegagalan ginjal (NRF). NaHS telah disuntik secara intraperitoneal pada dos 56 µmol/kg setiap hari selama 35 hari. Hipertensi telah diaruh di dalam tikus WKY dengan memulakan pemberian L-NAME secara oral dalam air minuman pada hari ke 8 dalam protokol kajian ini pada dos 40mg/kg selama 28 hari. Penyakit kegagalan ginjal akut (ARF) telah diaruh dengan suntikan tunggal cisplatin secara intraperitoneal pada dos 5 mg/kg. Penghalang cistationin gama liase (CSE) dL-propargilglicin (PAG) telah diberi pada hari ke-36 (hari eksperimen akut) secara suntikan tunggal intraperitoneal pada dos 50mg/kg. Haiwan telah dibahagikan kepada 4 kumpulan utama (i)WKY, (ii) L-NAME, (iii) WKY-RF dan (iv) L-NAME-RF. Semua kumpulan-kumpulan tersebut telah dipecahbagikan kepada tiga kumpulan kecil lagi iaitu (i) kumpulan kawalan, (ii) kumpulan rawatan NaHS dan (iii) kumpulan yang diberi PAG. Eksperimen kawalan masa juga telah dilakukan dengan menjalankan eksperimen sham di dalam kumpulan-kumpulan WKY-SHAM dan L-NAME-SHAM dimana iskemia tidak diaruh. Parameter-parameter data

fisiologi, hemodinamik sistemik dan fungsi ginjal telah diambil pada hari ke-0, 21 dan 35 di samping pengukuran H_2S di dalam plasma pada hari ke-0, 21 dan 36 kajian. Hemodinamik sistemik, tekanan darah kortikal ginjal (RCBP), halaju gelombang denyutan (PWV), parameter fungsi ginjal, penanda tekanan oksidatif, kepekatan ICAM-1 dan NF-kB juga telah diukur pada hari akut eksperimen (hari ke-36) di fasa pra-iskemia dan fasa reperfusi. Data diberikan sebagai $\text{min} \pm \text{S.E.M}$ dan telah dianalisis dengan menggunakan langkah-langkah berulang analisis varians (ANOVA) satu-hala dan diikuti dengan ujian pos hoc dengan singnifikasi $P < 0.05$. Pra-rawatan dengan NaHS telah membaikpulih parameter fungsi ginjal di dalam kumpulan ARF dan menurunkan hipertensi aruhan L-NAME secara signifikan (semua adalah $P < 0.05$). Tambahan pula, rawatan dengan NaHS telah membaikpulihkan paras kecederaan reperfusi iskemia ginjal (IRI) yang dibuktikan dengan pengurangan signifikan oleh penanda tekanan oksidatif (semua adalah $P < 0.05$), indeks ginjal dan peningkatan signifikan di dalam RCBP (semua adalah $P < 0.05$) yang diikuti IRI ginjal. Pra-rawatan dengan NaHS juga telah menurunkan kepekatan ICAM-1 dan NF-kB secara signifikan (semua adalah $P < 0.05$) selepas IRI ginjal. Kesimpulannya, H_2S mempunyai potensi anti oksidan seperti yang terbukti dalam kajian ini dengan menurunkan intensiti tekanan oksidatif yang dimana sebagai tindak balas telah menghalang pengaktifan NF-kB. Selain itu, H_2S juga mempunyai ciri-ciri anti radang yang dibuktikan di dalam kajian ini melalui penurunan kepekatan ICAM-1. Oleh itu, penemuan ini menunjukkan bahawa H_2S mempunyai kedua-dua anti-oksida dan anti-radang yang menyumbang kepada pengurangan dalam keterukan kerosakan IRI buah pinggang.

EFFECT OF EXOGENOUSLY ADMINISTERED HYDROGEN SULPHIDE (H₂S) ON PLASMA CONCENTRATION OF NUCLEAR FACTOR-KAPPA B (NF-κB) AND INTERCELLULAR ADHESION MOLECULE-1 (ICAM-1) IN A RAT MODEL OF RENAL ISCHEMIA REPERFUSION INJURY

ABSTRACT

The present study investigated the effect of exogenous administration of hydrogen sulphide (H₂S) donor, sodium hydrosulphide (NaHS) on the concentration of nuclear factor kappa-B (NF-κB) and inter cellular adhesion molecule-1 (ICAM-1) in renal ischemia reperfusion injury in normotensive *Wistar Kyoto* (WKY) non-renal failure (NRF) and renal failure (RF) rats as well as L-nitro-arginine-methyl-ester (L-NAME) induced hypertensive NRF and RF rats. NaHS was administered intraperitoneally at a dose of 56 μmol/kg on daily basis for 35 days. Hypertension was induced in WKY rats by starting oral administration of L-NAME in drinking water on day 8 of the study protocol at a dose of 40 mg/kg for 28 days. ARF was induced by single intraperitoneal injection of cisplatin at a dose of 5 mg/kg. Cystathionine gamma lyase (CSE) inhibitor dL-propargylglycine (PAG) was administered on day 36 (acute experiment day) by single intraperitoneal injection at a dose of 50 mg/kg. All the animals were divided into four main groups (i) WKY, (ii) L-NAME, (iii) WKY-RF and (iv) L-NAME-RF. All these groups were further sub-divided into three sub groups (i) control groups, (ii) NaHS treatment groups and (iii) PAG administered groups. Time control experiments were also performed by operating sham experiments in WKY-SHAM and L-NAME-SHAM groups in which ischemia was not induced. Physiological data, systemic haemodynamics and renal functional parameters were measured on days 0, 21 and 35 along with plasma H₂S

measurement on days 0, 21 and 36 of the study protocol. Similarly systemic haemodynamics, RCBP, PWV, renal functional parameters, oxidative stress markers, ICAM-1 and NF-kB concentration were also measured on acute experiment day (day 36) at pre-ischemic phase and reperfusion phase. Data, mean \pm SEM were subjected to repeated measure one-way ANOVA followed by Bonferroni *post hoc* test with significance at $P < 0.05$. Pre-treatment with NaHS improved renal functional parameters in ARF groups as well as decreased significantly (all $P < 0.05$) the L-NAME induced hypertension. Moreover, pre-treatment with NaHS reduced the severity of renal ischemia reperfusion injury (IRI) as evidenced by significant reduction (all $P < 0.05$) of oxidative stress markers, kidney index and significant increase (all $P < 0.05$) in RCBP following renal IRI. Similarly, pre-treatment with NaHS also decreased significantly (all $P < 0.05$) NF-kB and ICAM-1 concentration after renal IRI. In conclusion, H₂S has anti-oxidant potential as evidenced in the present study by reducing the intensity of oxidative stress which in response inhibited the activation of NF-kB. Similarly, H₂S has also anti-inflammatory properties as evidenced in the present study by the down regulation of ICAM-1 concentration. Hence, these findings indicate that H₂S has both anti-oxidant and anti-inflammatory properties which contribute to a reduction in severity of renal IRI damage.

CHAPTER 1

INTRODUCTION

1.1 Kidney

1.1.1 Anatomy of the kidney

Human beings have a pair of kidneys which are present on each side of the spine in the abdominal cavity. The left kidney is located at the vertebral level T12-L3 in the retroperitoneal space while, the right kidney is slightly lower than the left kidney. The position of the left kidney is approximately beneath the diaphragm posterior to the spleen. The right kidney is located beneath the diaphragm and posterior to the liver. An adrenal gland is present on the top of each kidney. Upper parts of the kidneys are partially protected by the 11th and 12th ribs. Both kidneys along with their adrenal glands are surrounded by two layers of fats the perirenal and the pararenal fat and the renal fascia (Walter & Boron, 2004). The weight of the adult male kidney ranges from 125 gm to 170 gm and 115gm to 155 gm in adult females. The kidney is approximately 11-14 cm long, 6 cm wide and 4 cm thick (Glodny et al., 2009). Kidney is a bean shaped structure consisting of concave and convex borders. The depression on the concave surface of the kidney is called the renal hilum. At the renal hilum the renal artery and renal vein enters into the kidney while, renal vein and the ureter leaves the kidney at this position. (Marieb & Hoehn, 2007). The cross section of the kidney shows two regions, the outer reddish brown

part called cortex and the inner darker brown part is called medulla. Nephron is the structural and functional unit of the kidney and extends across the cortex and the medulla (Shier, 2003). Each kidney consists of approximately 20 million nephrons. Nephron consists of glomerulus and the bowmans capsule and this portion is called the renal corpuscle and is located in the cortex. Renal corpuscle is then followed by the renal tubules which passes into medullary pyramids (Walter & Boron, 2004). The renal tubules consist of the proximal convoluted tubules, loop of henle and distal convoluted tubules. Tip of each pyramid empties the urine into the minor calyx which further empties urine into the major calyces and finally the major calyces empties urine into renal pelvis and then the ureter (Drake et al., 2005). Right and left renal artery supplies blood directly from the abdominal aorta into the respective kidneys. Despite small size of the kidneys they still receive approximately 20 % of the cardiac output. Each of the renal arteries divides into segmental arteries which branch further into the interlobar arteries which enter into the renal capsule and further extend into the renal columns. The arcuate arteries receive blood from the interlobar arteries that extend across the surface of the medulla and cortex. Each of the arcuate artery empties into various interlobular arteries which further extend into the afferent arterioles and these arterioles supplies blood into the glomeruli (Walter & Boron, 2004). Once the blood is filtered it passes through small venules followed by interlobular veins. From these veins blood is supplied to arcuate veins and then to interlobar veins which finally empty into the renal vein. Blood from both renal veins returns into inferior vena cava. (Applegate, 2000; Meyer et al., 2004; Vander, 1995).




Figure 1.1: Anatomy of the human kidneys. This picture has been adopted from Gray, Henry. 1918. *Anatomy of the human body* (Gray, 1918).

1.1.2 Renal physiology

The function of the kidneys is to excrete a wide range of waste products produced by the process of metabolism like urea, nucleic acid and uric acid. Kidneys are also responsible for the reabsorption of many vital nutrients like glucose and amino acids. Kidneys play a key role in the acid base homeostasis and hormones like erythropoietin is also produced by the kidneys (Dantzler, 1989). Kidneys play a vital role in the regulation of blood pressure through the renin angiotensin aldosterone system (Hall & Guyton, 2011). Kidneys contribute in maintaining blood pressure along with nervous, cardiovascular and endocrine systems (Germann et al., 2005). Nephron is responsible for the process of filtration followed by reabsorption and finally secretion. The process of filtration takes place at the renal corpuscle. From

the blood larger proteins and various cells get filtered in the process of filtration. Thus, the glomerulus filtrate is produced which finally forms the urine. The production of the ultra-filtrate is approximately 180 liters per day of which a large portion is reabsorbed by the kidneys. Thus the production of urine is only about 2 liters a day (Guyton, 1991).

1.2 Ischemia reperfusion injury

1.2.1 Ischemia

It is a condition in which blood supply to an organ or tissue is reduced or restricted. This results in deficiency of oxygen and glucose supply which is necessary for the process of cellular metabolism (Siemionow & Arslan, 2004). Ischemic injury is the stoppage or interruption in the arterial blood supply with the sudden oxygen shortage to the cells. Thus hypoxia is produced along with augmentation of metabolic products (Kosieradzki & Rowinski, 2008).

There are different types of ischemia like (a) myocardial ischemia, (b) cerebral ischemia, (c) critical limb ischemia, (d) hepatic ischemia and (e) renal ischemia.

1.2.1 (a) Myocardial ischemia

It is a condition in which the heart is unable to maintain the balance between blood supply and the demand of oxygenated blood to myocardium itself due to blockade or narrowing of the coronary arteries (Mohan, 2010). Myocardial ischemia is also called ischemic heart disease (IHD).

1.2.1 (b) Cerebral ischemia

A condition in which the blood supply to the brain is not sufficient to meet the needs for the metabolic processes (Ames et al., 1968). Cerebral ischemia is also called brain or cerebrovascular ischemia.

1.2.1 (c) Critical limb ischemia

It is the condition in which there is insufficient blood supply to the hands, legs and feet due to severe blockade of the arteries. As a result there is pain at rest in the form of continuous burning sensation of the legs or feet (Schanzer & Conte, 2010). There are also sometimes ischemic skin ulcers and even gangrene (Minar, 2009).

1.2.1 (d) Hepatic ischemia

It is the condition in which there is interruption of blood supply to the liver as a result the liver does not receive enough blood supply or oxygen (Lentsch et al., 2000).

1.2.1 (e) Renal ischemia


Renal ischemia is the condition in which there is complete cut off or reduced blood supply thus, a hypoxic state is developed in the kidneys and due to this insufficient oxygen the injury is initiated by the breakdown of ATP. As a result of this, adenosine and other metabolic products of nucleotides move out of the cells causing ATP production to be delayed once the blood is reperfused back (Gaudio et

al., 1986). Functional and structural integrity of all cells is dependent upon cellular tight junctions and microfilaments and its functioning requires a continuous supply of energy. Once the energy supply is stopped protein subunits breakdown and they leave the tight junction of the cells and cellular microfilaments (Hays, 1992). There is evidence that the concentration of free intercellular ions increases during ischemia (Lee & Allen, 1992) and the injury to kidneys caused by the ischemic condition is the main reason for acute renal failure (Basile et al., 2003). Various organ transplantation failures are due to this ischemic damage (Wolfs et al., 2005). Some of the effects of ischemia at the cellular level are: altered membrane potential, changes in ion distribution, cytoskeletal disorganization, cellular swelling, cellular acidosis, increased hypoxanthine production and decreased phosphocreatinine, glutathione and ATP production (Collard & Gelman, 2001).

1.2.2 Reperfusion injury

Reperfusion injury is the damage induced by the reperfused blood as it is restored after the ischemic phase. Reperfusion injury is the result of cell activation and the injury occurred during ischemia (Bilzer et al., 1999). In reperfusion phase the permeability of various capillaries and arterioles becomes much more high and thus the tissues becomes more susceptible to fluid filtration. After the reperfusion process the concentration of reactive oxygen species is increased because they are produced in greater quantity by the activated endothelial cells but the nitric oxide production is reduced. This imbalance between the reactive oxygen species and nitric oxide production initiates the inflammatory response (Carden & Granger, 2000). Reperfusion injury is the effective continuation stage of the injury induced by ischemia. This injury may occur within hours or days after ischemia. Cellular

necrosis and apoptosis is accompanied together by the cellular regeneration and repairing processes which requiring energy. The activation of caspase and liberation of cytochrome C occurs as early as 5 minutes after the process of reperfusion (Hoek et al., 2003). The concentration of free intercellular calcium ion which was increased during early ischemia starts returning back to the normal level. Due to this the cells start recovering from early damage done in ischemic phase. But due to continuous increase of the calcium ion an irreversible injury starts (Lee & Allen, 1992). After reperfusion there is a quick release of free radicals. The main source for the production of free radicals is respiratory chain enzymes. Superoxide is formed from free oxygen which reacts with reduced ubiquinone. Superoxide is metabolized by catalyse to produce hydrogen peroxide or this superoxide is metabolized to hydroxyl radical where ferrous or copper acts as catalyst (Kosieradzki & Rowinski, 2008). After reperfusion, the superoxide free radical $\cdot\text{O}_2^-$ is produced in large quantities. This reactive superoxide specie produces more hydroxyl radical $\cdot\text{OH}$, through Fenton and Haber-Weiss reactions and uses iron as a reaction catalyst (Zweier, 1988).



These highly reactive free radicals cause the peroxidation of the mitochondrial and cellular membranes of the phospholipids and hence induce endothelial injury in reperfusion phase. This causes an increase in the extent of injury of endoplasmic reticulum which causes the production of autophagosomes and then cellular degradation. This increases lysosomal activity of the proteases and causes further necrosis and aptoposis (Kosieradzki & Rowinski, 2008). Metabolites of reactive oxygen species and polymorphonuclear leukocytes have been reported to

be involved in the pathophysiology of ischemia reperfusion injury (Zimmerman & Granger, 1994). The reactive oxygen species produced during ischemia reperfusion injury is responsible for the cellular damage through lipid peroxidation (Jaeschke, 1998). It has also been cited that one of the most important hypothesis of cellular damage by the reactive oxygen species is through inhibition of lipid peroxidation (Jaeschke, 2000). Cellular damage caused by the reactive oxygen species is due to the degradation and oxidation of proteins, lipid peroxidation and also due to the damage of DNA. These redox signalling injuries activates the pathways of transduction which in response initiates the process of injury (Fan et al., 1999). It has also been hypothesized that xanthine oxidase and mitochondria is a potential source of reactive oxygen species formation (Jaeschke, 1996). One study has suggested that generation of reactive oxygen species by phagocytic cells may be one source for the cellular injury but different types of inflammatory mediators may also be involved in the reperfusion injury (Jaeschke et al., 1992). These reactive oxygen species are responsible for the cellular damage and also act as second messenger for the initiation of inflammation. The major site for the production of reactive oxygen species is mitochondria. The consumption of oxygen and production of energy is achieved by the electron transport chain. In this transport chain the molecular oxygen is reduced to water. The ischemic reperfusion injury in mitochondria is responsible for the electron transport chain decoupling. As a result of this decoupling large quantity of reactive oxygen species is generated and released (Fan et al., 1999). So, reactive oxygen species is an important factor during ischemia reperfusion injury. Ischemic reperfusion injury is also a major factor for the increased morbidity and mortality in numerous clinical conditions specially in organ transplantation failure (Fan et al., 1999).

1.3 Renal failure

Renal failure is characterized by renal dysfunction in which kidneys are unable to perform filtration of waste products in the blood properly (Kajbaf et al., 2013). There are two major types of renal failure discussed below.

1.3.1 Chronic renal failure

Chronic renal failure is a condition which is characterized by the kidney injury and glomerular filtration rate becomes lower than 60 mL/min for a period of three consecutive months or a period of more than three months. In chronic renal failure an irreversible sequence of damages occur which causes last stage kidney disease (Parmar, 2002). Chronic kidney injury involves the irreversible loss of kidney function involving slow deterioration of parenchymal cells of the kidney leading to nephronal damage during this process (Mohan, 2010).

1.3.2 Acute renal failure

In acute renal failure (ARF), renal function is affected or declined in a shorter span of time between hours to days and may result in kidney failure. The kidney is unable to perform excretion of various waste products as well as balance and maintenance of electrolytes and fluids (Ympa et al., 2005). Acute renal failure involves rapid onset of renal dysfunction mainly indicated by anuria or oliguria. ARF is also characterized by rapid increase of blood creatinine and urea concentration and uremia may also occur subsequently (Mohan, 2010). In acute renal failure the concentration of creatinine in serum increases 50 % from the

baseline value (Evenepoel, 2004). Various factors which induce ARF are hypovolemia, sepsis, liver dysfunction, damaged renal perfusion, vascular blockade and drugs (Ympa et al., 2005). Three main causes of ARF has been identified (Mohan, 2010) which are discussed below.

1.3.2 (a) Pre-renal cause

It is a reversible type of renal failure and reduced arterial blood flow to the kidneys is the main reason for pre-renal azotaemia (Evenepoel, 2004). It is characterized by reversible increase of plasma creatinine and blood urea. Decreased renal reperfusion is the cause of pre-renal azotaemia due to which the glomerular filtration rate becomes low (Lameire, 2005). It occurs in response to low extracellular volume and increased activity of adrenergic receptors and may accompany heart failure, sepsis, cirrhosis or nephrosis (Blantz, 1998).

1.3.2 (b) Intra-renal cause

In intra renal acute renal failure damage to the renal tissues occurs specially to the renal arteries and arterioles. Moreover, it is characterised by injury to glomeruli and acute tubular necrosis (ATN) (Mohan, 2010). Various toxins and ischemia is mainly responsible for the tubular injury occurring in intra-renal ARF (Wali & Henrich, 2002).

1.3.2 (c) Post-renal cause

Post-renal cause involves blockade to urine flow in the renal tract. This obstruction to the flow of urine results from the formation of a mass inside the lumen or there may be any external compression on the urinary tract, urethra, ureter or bladder which leads to renal infection (Mohan, 2010).

1.3.3 Drugs-induced acute renal failure

ARF may be induced by different types of therapeutic agents. Acute interstitial nephritis results from various drugs which causes allergic reactions. This may further cause inflammation and tubular injury. Therapeutic agents that cause ATN involve toxicity to the tubular epithelium directly with the induction of inflammation. Some other injuries induced by various medications involves crystal nephropathy, acute nephrocalcinosis and osmotic nephropathy (Markowitz & Perazella, 2005). Therapeutic agents that cause pre-renal acute renal failure include NSAIDS, cyclosporine and diuretics etc (Lameire, 2006). Drugs responsible for the post-renal causes of acute renal failure include methysergide, acyclovir, sulphonamide and triamterene etc (Perazella, 1999). Majority of drugs and chemicals are involved in the induction of intra-renal ARF (Woolfson & Hillman, 2000; Zager, 1997). Amongst various tubular injuries ATN is the most prominent one that occurs during intra-renal injury of acute renal failure (Woolfson & Hillman, 2000). Various chemical agents and drugs that cause ATN are antibiotics, amphotericin B, aminoglycosides, cyclosporine A, mannitol, cisplatin and polyethylene glycol etc

1.3.3 (a) Cisplatin induced acute renal failure

Cisplatin belongs to the class of platinum containing anti-cancer drugs used for solid malignancy treatment. Cisplatin is also used in the treatment of lung cancer, bladder cancer, ovarian cancer, cervical cancer, germ cell tumours, lymphomas and sarcomas. Various models of ARF in laboratory animals for different physiological and pharmacological studies have been achieved through cisplatin administration (Atessahin et al., 2005; Rubera et al., 2013; Tayem et al., 2006). Tubular filtration and secretion are mainly responsible for the excretion of cisplatin whereas peritubular uptake is responsible for cisplatin accumulation in the kidneys (Annie et al., 2005). So, cisplatin does not undergo the process of tubular reabsorption. Proximal tubular cells of outer medulla and inner cortex are the main site for cisplatin toxicity. Mostly cisplatin-induced renal injury occurs at S3 segment of nephrons (Leibbrandt et al., 1995). It has been reported by various studies that renal toxicity occurs by injecting single dose of cisplatin. Renal toxicity causes an increase in serum creatinine and blood urea nitrogen. Cisplatin renal toxicity induces necrosis and apoptosis of proximal convoluted tubules (Dobyan et al., 1980). Cisplatin induced renal toxicity causes ATN and sloughing of epithelial cells of the renal tubules (Al-Harbi et al., 1995), decreased glomerular filtration rate (Kang et al., 2004), damage to proximal tubules (Jones et al., 1985) and increased resistance to renal blood vessels (Matsushima et al., 1998). Cisplatin induce renal failure also involves the role of reactive oxygen species (ROS) specially hydroxyl radicals and superoxide anion because it has been reported that oxidative stress is induced by cisplatin due to the production of free radicals (Badary et al., 2005; Brahmi et al., 2012). Increased peroxidation of lipid molecules is also a hallmark of cisplatin induced renal toxicity (Paul et al., 1991; Vaziri et al., 2002). It has also been reported

that ROS involves in the inhibition of various anti-oxidant enzymes in the kidneys (Masuda et al., 1994) and specially affecting the concentration of renal glutathione level (Jin & Lindup, 1993).

1.4 Hypertension

Chronic increase of systemic arterial blood pressure above defined limits is defined as hypertension. Thus, hypertension is a chronic medical condition sometimes also called as high blood pressure or arterial hypertension. The border line between normal pressure and hypertension is 140/90 mmHg (Vander & Luciano). So, hypertension is sustained increase of systolic blood pressure which exceeds 140 mmHg and diastolic blood pressure exceeds 90 mmHg in adults. Hypertension is a common cause of various cardiovascular diseases like coronary artery disease, cardiac failure and dissecting aortic aneurysm. It is also a risk factor for renal insufficiency and stroke (Laurence et al., 2008).

Table 1.1: Classification of hypertension for adults in Malaysia (NHMS 3, 2006)³ redrawn by using Ms Word office from Clinical Practice Guidelines for Management of Hypertension (4th edition) issued in 2013 available online on [http://www.moh.gov.my/attachments/CPG_Management_of_Hypertension_4th Edition.pdf](http://www.moh.gov.my/attachments/CPG_Management_of_Hypertension_4th_Edition.pdf)

Classification	Systolic B.P (mm Hg)	Diastolic B.P (mm Hg)
Optimal	< 120 and	< 80
Normal	< 130 and	< 85
High normal	130 – 139 and/or	85 – 89
Hypertension		
Stage I	140 – 159 and/or	90 – 99
Stage II	160 – 179 and/or	100 – 109
Stage III	≥ 180 and/or	≥ 110

1.4.1 Primary hypertension

It is the type of hypertension for which the cause or origin is unknown. It is also called essential hypertension. Most of the patients having essential hypertension have a family history indicating hereditary tendency (Guyton & Hall, 2006). It has been cited in various articles that genetics is a key factor in the primary hypertension (Feinleib et al., 1977; Longini et al., 1984). Demographical and environmental causes are the factors mainly responsible for genetically induced hypertension (Oparil et al., 2003). Obesity may also be the cause for the primary hypertension (Chiong et al., 2008).

1.4.2 Secondary hypertension

It is the type of hypertension for which the cause or origin is known (Chiong et al., 2008; Guyton & Hall, 2006). About 5-10 % of the population suffer from secondary hypertension. The major causes of secondary hypertension are various diseases some of them are given as follow.

Renal diseases like renal parenchymal disease, renin producing tumor and renal vascular disease etc. Cardiovascular diseases like rigidity of aorta and coarctation of aorta. Endocrine diseases like hypothyroidism, hyperthyroidism, primary aldosteronism and acromegaly etc. Acute stress related hypertension, pregnancy related hypertension, obstructive sleep apnea and drugs induced hypertension (Chiong et al., 2008).

1.4.2 (a) L-NAME induced hypertension

L-nitro-arginine methyl ester (L-NAME) induced hypertension is widely used as an animal model for secondary hypertension in various *in vivo* studies. L-NAME given orally to the laboratory animals induces hypertension and thus presents as a secondary hypertension model in laboratory rats (Khayyal et al., 2002). L-NAME is a nitric oxide synthase (NOS) inhibitor and chronic treatment with L-NAME induces arterial hypertension in rats. Systemic blood pressure and vascular tone is mainly regulated by the endothelium which is involved in the production of various vasodilating and vasoconstricting factors like nitric oxide (NO), angiotensin II, endothelins and prostacyclin (Bernatova et al., 2000). Various studies have shown that L-arginine is the precursor of NO which mediates various gastrointestinal, neural and cardiovascular functions. L-arginine is metabolised to NO by NOS

(Mourad et al., 1996). NO in the blood vessels is mainly produced from the isoforms of NOS either by endothelial nitric oxide synthase (eNOS) or nitric oxide synthase-3 (NOS3). More studies have also reported that NO is produced endogenously and its continuous genesis plays a key role in the maintenance of vascular and gastric integrity (Tepperman & Whittle, 1992; Whittle et al., 1990). Inhibition of platelet aggregation, inhibition of neutrophil endothelium adhesion, regulation of apoptosis, and vasodilation is mainly induced by NO (Rosselli et al., 1998). L-NAME inhibits eNOS because it is an analogue of the L-arginine and thus competes with it on eNOS binding sites (Rees et al., 1990). L-NAME causes the inhibition of eNOS thus inactivating NO. It also inhibits nNOS and thus stimulates sympathetic nervous system. In order to maintain hypertension L-NAME activates renin-angiotensin system (Biancardi et al., 2007). Moreover, various mechanisms of L-NAME induced hypertension have also been reported like, L-NAME causes an increase in the level of endothelin-1 (Amours et al., 1999) and also blocks Na⁺K⁺-ATPase channels (Rossoni et al., 2003) and thus contributes to the induction of hypertension. It is also documented that L-NAME may act as an antagonist for the muscarinic receptors and may also effect the activity of prostaglandins (Buxton et al., 1993). Long term treatment with L-NAME *in vivo* studies show structural changes in the vasculature and may also cause myocardial hypertrophy (Usui et al., 1999). Decrease in the endogenous production of NO may cause oxidative stress (Kurose et al., 1995; Niu et al., 1994). Increased oxidative stress in the rats treated with L-NAME is reported further evidenced by increased protein oxidation of the membrane, enhanced NADPH oxidase-1 (NOX-1) and NADPH oxidase-2 (NOX-2) and also augmented concentration of superoxide dismutase (SOD) which is an anti-oxidant glutathione (Bell et al., 2008). Inhibition of NO by L-NAME may cause the production of

reactive oxygen species (ROS) specially superoxide anion (O_2^-) (Kitamoto et al., 2000).

1.5 Inflammation

Inflammation is the local response of the tissues to any injury induced by any harmful agent or stimuli and is therefore a defensive mechanism of the body which involves the removal of the harmful agents or reducing the chances of spreading of these injurious agents (Mohan, 2010). It is the process in which body response to various stimuli like irritants, various pathogens and some damaged cells (Ferrero et al., 2007). During inflammation there is release of different types of mediators by injured or damaged cells in response to heat, trauma or different types of chemicals. This response initiates secondary changes in the injured neighbouring tissues and this whole physiological response in the tissues is called as the process of inflammation (Guyton & Hall, 2006). Inflammation is the protective response of the body which is participated by blood vessels, host cells, proteins and different type of mediators. This protective effect is carried out by initially diluting, destroying or neutralizing the injurious agents (Kumar et al., 2012). The function of inflammation is to combat the initial source of the injury done to the cells or tissues to provide defense against necrosis and to eradicate various cells or tissues damaged during this process. Inflammation also induces repairing of the damaged tissues after the initial insult. The area where the inflammation is going on is marked with swelling, redness, pain and heat sensation. Inflammation is the natural response of the body and referred to as the mechanism of innate immunity (Abbas et al., 2012). The ability of the body to induce inflammation is necessary for its survival against

various foreign pathogens and different kind of injuries evoked by various stimuli like physical injuries, antibodies, various pathogens and different kind of infections. The inflammatory process during normal conditions and in various diseased states may be induced and maintained without any beneficial effects or may cause some noxious consequences (Laurence et al., 2008). The pathophysiology of inflammation involves the excessive blood flow to the damaged tissues due to increased vasodilation of blood vessels. Inflammation is also characterized by the movement of a large number of leukocytes in to the effected tissues. Due to increased permeability of the capillaries there is excessive leakage of fibrinogen which results in the formation of fluid clotting in interstitial spaces. Various inflammatory mediators stimulate the immune system. Thus, with in a period of only a few hours the macrophages start engulfing the damaged tissues. But during this defensive process they further damage the neighbouring normal tissues (Guyton & Hall, 2006). During the process of inflammation there is an initial inflammatory response to different inflammatory mediators and the second one is the healing process of the injured tissues. So, these steps cause considerable damage to the tissues. Immune system and inflammation are the defensive mechanisms of the body and both are interrelated to each other. Inflammation results from any immune reaction while activation of immune system is a necessary factor before the process of inflammatory response (Mohan, 2010). One of the most popular phenomenon of inflammation is the "walling off" the surrounding undamaged tissues from the injured tissues. Fibrinogen clots block the lymphatic and the interstitial spaces of the damaged area so after a shorter period of time there is an increased flow of fluids in these spaces. The advantage of walling-off mechanism is that it delays the spreading of various pathogens and different injurious products (Guyton & Hall, 2006). Inflammation is

characterized by three specific basic phases with each phase involving different mechanisms. The initial one is the acute phase of inflammation where an increased vasodilation and enhanced permeability of the capillaries occurs. The second one is the subacute phase with a delayed inflammatory response that involves migration of different phagocytic cells and leukocytes to the inflamed area. Chronic proliferative phase is the third and last phase which is characterized by degeneration of the tissues. Fibrosis also takes place in this stage (Laurence et al., 2008). Without the process of inflammation there will be no monitoring of the infections and will worsen with the passage of time. Secondly, without inflammation there will be no healing process (Kumar et al., 2012). There are two types of inflammation namely acute and chronic inflammation as discussed below.

1.5.1 Acute inflammation

Acute inflammation is characterized by the rapid transport of leukocytes and plasma proteins to the injurious area. Once the leukocytes are migrated at the site of injury they start clearing the area from the invaders and start engulfing and removing the necrotic tissues (Kumar et al., 2012). The duration of acute inflammation is very short which may be less than a period of two weeks. Acute inflammation is typified by plasma and fluid accumulation at the area of injury, platelet activation and neutrophil infiltration. Sometime the response of acute inflammation is more serious and that is why it is called fulminant acute inflammation (Mohan, 2010). Acute inflammation is divided in to two events, vascular and cellular changes.

1.5.1 (a) Vascular changes

It involves the changes in the vascular capabilities which cause increased vasodilation. Vascular changes are also characterized by the enhanced permeability of the capillaries which results in the leakage of plasma proteins from the blood vessels. Furthermore, vascular changes are accompanied by stimulating endothelial cells as a result of this activation leukocytes start adhering to these endothelial cells and starts rolling and migration along the blood vessels wall (Kumar et al., 2012).

1.5.1 (b) Cellular events

Vascular changes are followed by cellular events which are characterized by the infiltration of leukocytes from the wall of blood vessels. After this they enter into the injury zone and start gathering in large numbers over there. The gathered leukocytes are activated and they start the removal of invaded harmful agents. The major leukocytes that participate in the acute inflammation are polymorphonuclear leukocytes (neutrophils) (Kumar et al., 2012).

Various mediators can induce the response of acute inflammation. Amongst them viral, bacterial, parasitic and fungal infections are more common triggers. Moreover, different kind of foreign bodies like dirt, crystal deposits and splinters etc can also induce acute inflammation. Different chemical substances, physical trauma or certain environmental factors may also induce acute inflammation. Numerous conditions of ischemia are also responsible for the induction of acute inflammation (Kumar et al., 2012).